Sickle Cell Disease Market Size, Share, Epidemiology and Market Forecast 2030
Sickle cell disease (SCD) is an inherited red blood cell disorder caused by a structural abnormality of haemoglobin called sickle haemoglobin (HbS) which encodes haemoglobin subunit u03b2. HbS is inherited in an autosomal recessive way and can occur due to homozygosity for HbS (HbSS). HbS is functional and soluble when oxygenated, but upon deoxygenation, it polymerizes, leading to the generation of deformed red blood cells known as sickled cells and dense erythrocytes. The current therapies used to prevent the complications of the disease vary in their effectiveness and are associated with serious risks and tolerability issues. Besides this, SCD presents with large unmet medical needs, with no disease-modifying treatment. Key Highlights of the Sickle Cell Disease Market Report According to DelveInsightu2019s analysis, no gender bias has been observed in the case of Sickle cell disease A study by Gregory J. Kato et al., titled u201cSickle cell diseaseu201d quoted that demographic projections estimated that the annual number of newborn babies with SCA worldwide will exceed 400,000 by 2050. According to the Centre for Disease Control and Prevention (CDC), it is estimated that SCD affects approximately 100,000 Americans. It occurs among about 1 out of every 365 Black or African-American births, about 1 out of every 16,300 Hispanic-American births, and about 1 in 13 Black or African-American babies are born with sickle cell trait. Sickle Cell Disease Market The Sickle Cell Disease market report provides a comprehensive analysis of the historic, current, and forecasted Sickle Cell Disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. For more details visit: https://www.delveinsight.com/report-store/sickle-cell-disease-market
39 views • 2 slides